Epcoritamab Is Superior in Third-Line Follicular Lymphoma With Potential to Move Into Earlier Lines.
- Published in:
- 2024
- By:
- Publication type:
- Interview
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 10
Results: 17
1
2
Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 22
- By:
- Publication type:
- Article
3
Mitazalimab/mFOLFIRINOX Generates Responses in Treatment-Naive mPDAC.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 64
- By:
- Publication type:
- Article
4
Perioperative Pembrolizumab/ Chemo Regimen Yields Superior OS in Resectable Gastric Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 60
- By:
- Publication type:
- Article
5
Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 58
- By:
- Publication type:
- Article
6
Dostarlimab Combo Generates PFS Benefit in Primary/Recurrent Endometrial Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 56
- By:
- Publication type:
- Article
7
CANCER CARE IN 2024: Striving to Overcome the Challenges.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 54
- By:
- Publication type:
- Article
8
THE IMPORTANCE OF ORAL MEDICINE: Evaluation and Treatment.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 53
- By:
- Publication type:
- Article
9
RLY-2608 Uses PI3Kα Mutant-- Specific Inhibition to More Safely Treat Breast Cancer and Other Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 38
- By:
- Publication type:
- Article
10
Tumor-Killing Technology in Head and Neck Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 52
- By:
- Publication type:
- Article
11
Optimize Interventions to Get a Step Ahead of Financial Toxicity in Cancer Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 49
- By:
- Publication type:
- Article
12
The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 34
- By:
- Publication type:
- Article
13
Analyzing the "RAS Pie" for Methods to Target Mutations in GI Cancers.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 31
- By:
- Publication type:
- Article
14
Subanalysis Supports Imetelstat for Transfusion-Dependent Low-to Intermediate-1--Risk MDS.
- Published in:
- 2024
- By:
- Publication type:
- Interview
15
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 8
- Publication type:
- Article
16
PRECISION CANCER MEDICINE: The Past, Present, and Future.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 6
- By:
- Publication type:
- Article
17
Actionable Mutations and Potential Biomarkers Emerge Across Cancer Types.
- Published in:
- OncologyLive, 2024, v. 25, n. 10, p. 4
- By:
- Publication type:
- Article